Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Interventional × LB100 × Clear all

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

Cyclophosphamide 1320 Cisplatin 1241 Paclitaxel 1164 Radiotherapy 1138 Carboplatin 1095 Gemcitabine 1082 Docetaxel 990 Bevacizumab 925 Fluorouracil 796 Doxorubicin 703 Dexamethasone 663 Capecitabine 654 Rituximab 644 Oxaliplatin 623 Etoposide 600 Irinotecan 571 pembrolizumab 564 Filgrastim 552 Leucovorin 519 Cytarabine 517 Nivolumab 476 Vincristine 455 Prednisone 425 Bortezomib 412 Erlotinib Hydrochloride 411 Cetuximab 407 Trastuzumab 399 Methotrexate 379 Lenalidomide 368 Pemetrexed 365

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01837667 2017-01-24

Phase I Study of LB-100 With Docetaxel in Solid Tumors

Lixte Biotechnology Holdings, Inc.

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡